A multicenter, randomized, double-blind study of the efficacy and safety of calcipotriene foam, 0.005%, vs vehicle foam in the treatment of plaque-type psoriasis of the scalp

Journal of Drugs in Dermatology

Volumn 12, Issue 3, 2013, Pages 300-306

  Feldman, Steven R ^a   Eastman, William J ^b   Brundage, Thomas ^b   Mills, Mary ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b Stiefel Laboratories Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIPOTRIOL;

ADULT; APPLICATION SITE ERYTHEMA; APPLICATION SITE PAIN; APPLICATION SITE PRURITIS; APPLICATION SITE REACTION; ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; FEMALE; HUMAN; INVESTIGATOR STATIC GLOBAL ASSESSMENT SCORE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARALLEL DESIGN; PLAQUE THICKNESS; PLAQUE TYPE PSORIASIS; PRURITUS; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; SCALING; SCALP; SKIN DISEASE; THICKNESS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CALCITRIOL; CHILD; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; ERYTHEMA; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; SCALP DERMATOSES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84874586770     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. van de Kerkhof PC, Franssen ME. Psoriasis of the scalp. Diagnosis and management. Am J Clin Dermatol. 2001;2(3):159-165.
2. Naldi L, Rzany B. Psoriasis (chronic plaque). Clin Evid (Online). 2009;2009. pii: 1706.
3. Chan CS, Van Voorhees AS, Lebwohl MG, et al. Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2009;60(6):962-971.
4. Kircik LH, Kumar S. Scalp psoriasis. J Drugs Dermatol. 2010;9(8 Suppl ODAC Conf Pt 2):s101-s105.
5. Feldman SR, Housman TS. Patients' vehicle preference for corticosteroid treatments of scalp psoriasis. Am J Clin Dermatol. 2003;4(4):221-224. (Pubitemid 36506427)
6. Kragballe K, Wildfang IL. Calcipotriol (MC 903), a novel vitamin D3 analogue stimulates terminal differentiation and inhibits proliferation of cultured human keratinocytes. Arch Dermatol Res. 1990;282(3):164-167. (Pubitemid 20155219)
7. Franz TJ, Parsell DA, Halualani RM, Hannigan JF, Kalbach JP, Harkonen WS. Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. Int J Dermatol. 1999;38(8):628-632. (Pubitemid 29404798)
8. Franz TJ, Parsell DA, Myers JA, Hannigan JF. Clobetasol propionate foam 0.05%: a novel vehicle with enhanced delivery. Int J Dermatol. 2000;39(7):535-538. (Pubitemid 30614283)
9. Feldman SR, Matheson R, Bruce S, et al; U0267-301 & 302 Study Investigators. Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaquetype psoriasis: results of two multicentre, randomized, double-blind, vehiclecontrolled, phase III clinical trials. Am J Clin Dermatol. 2012;13(4):261-271.
10. Langner A, Staçpór W, Ambroziak M. Vitamin D3 metabolites and analogues in the treatment of scalp psoriasis. J Dermatol Treat. 1998;9(Suppl 3):S41-S45.
11. Segaert S, Duvold LB. Calcipotriol cream: a review of its use in the management of psoriasis. J Dermatolog Treat. 2006;17(6):327-337. (Pubitemid 46895590)
12. Duweb G, Alhaddar J, Abuhamida M. Calcipotriol solution in scalp psoriasis. Int J Tissue React. 2005;27(4):163-166. (Pubitemid 43056216)
13. van de Kerkhof PC, Kleinpenning MM, Gerritsen RM. Scalp psoriasis. In: Koo J, Lee CS, Lebwohl MG, editors. Mild-to-Moderate Psoriasis. 2nd ed. New York, NY: Informa Healthcare USA, Inc; 2009.
14. Feldmann RJ, Maibach HI. Percutaneous penetration of steroids in man. J Invest Dermatol. 1969;52(1):89-94.
15. Feldmann RJ, Maibach HI. Regional variation in percutaneous penetration of 14C cortisol in man. J Invest Dermatol. 1967;48(2):181-183.
16. Bergstrom KG, Arambula K, Kimball AB. Medication formulation affects quality of life: a randomized single-blind study of clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.05% for the treatment of psoriasis. Cutis. 2003;72(5):407-411. (Pubitemid 37550149)
17. Feldman SR, Fleischer AB Jr, Cooper JZ. New topical treatments change the pattern of treatment of psoriasis: dermatologists remain the primary providers of this care. Int J Dermatol. 2000;39(1):41-44. (Pubitemid 30113540)
18. Lebwohl M, Siskin SB, Epinette W, et al. A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis. J Am Acad Dermatol. 1996;35(2 Pt 1):268-269.
19. Lebwohl M, Menter A, Koo J, Feldman SR. Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol. 2004;50(3):416-430. (Pubitemid 38316135)
20. Sorilux Foam prescibing information. http://www stiefel com/us/US-Sorilux- Foam pdf. Accessed October 14, 2011.